Our Pipeline

BIOSIMILAR DESCRIPTION REFERENCE PRODUCT PRIMARY CONDITIONS

ABP 501
(biosimilar adalimumab)

Anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody
  • Moderate-to-severe rheumatoid arthritis
  • Moderate-to-severe chronic plaque psoriasis
  • Adult moderate-to-severe Crohn’s disease
  • Moderate-to-severe ulcerative colitis
  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Moderate-to-severe polyarticular juvenile idiopathic arthritis
  • Moderate-to-severe hidradenitis suppurativa
  • Intermediate, posterior, and panuveitis non-infectious uveitis

ABP 980
(biosimilar trastuzumab)

Anti-HER2 monoclonal antibody
  • HER 2+ breast cancer
  • HER 2+ gastric cancer

ABP 215
(biosimilar bevacizumab)

Anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody
  • Colorectal cancer
  • Non-squamous non-small cell lung cancer
  • Glioblastoma
  • Renal cell carcinoma
  • Breast cancer
  • Ovarian cancer

ABP 798
(biosimilar rituximab)

Anti-CD20 monoclonal antibody
  • Non-Hodgkin’s lymphoma
  • Chronic lymphocytic leukemia
  • Rheumatoid arthritis
  • Granulomatosis with polyangiitis
  • Microscopic Polyangiitis

ABP 710
(biosimilar infliximab)

Anti-tumor necrosis factor-alpha
(anti-TNF) monoclonal antibody
  • Rheumatoid arthritis
  • Plaque psoriasis
  • Crohn’s disease
  • Ulcerative colitis
  • Psoriatic arthritis
  • Ankylosing spondylitis

ABP 494
(biosimilar cetuximab)

Anti-epidermal growth factor receptor
(anti-EGFR) monoclonal antibody
  • Colorectal cancer
  • Head and neck cancer

 

Notes:

  • Approved product indications will differ by regulatory agency
  • Amgen has an additional 3 biosimilar programs in product development, which are undisclosed at this time
Inflammation
Oncology